137 related articles for article (PubMed ID: 28640529)
21. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
22. Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.
Rashidi M; Esmaily S; Fiane AE; Gude E; A Tønseth K; Ueland T; Gustafsson F; Eiskjær H; Rådegran G; Dellgren G
Int J Cardiol; 2016 May; 210():80-4. PubMed ID: 26938682
[TBL] [Abstract][Full Text] [Related]
23. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.
Norum HM; Michelsen AE; Lekva T; Arora S; Otterdal K; Olsen MB; Kong XY; Gude E; Andreassen AK; Solbu D; Karason K; Dellgren G; Gullestad L; Aukrust P; Ueland T
Am J Transplant; 2019 Apr; 19(4):1050-1060. PubMed ID: 30312541
[TBL] [Abstract][Full Text] [Related]
24. Everolimus-based Immunosuppression Possibly Suppresses Mean Fluorescence Intensity Values of De Novo Donor-specific Antibodies After Primary Kidney Transplantation.
Narumi S; Watarai Y; Goto N; Hiramitsu T; Tsujita M; Okada M; Futamura K; Tomosugi T; Nishihira M; Sakamoto S; Kobayashi T
Transplant Proc; 2019 Jun; 51(5):1378-1381. PubMed ID: 31056252
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
26. Renal Function Changes Under Everolimus Plus Cyclosporine or Everolimus Plus Tacrolimus After Heart Transplantation.
Chiang TY; Tsao CI; Wang SS
Transplant Proc; 2018 Nov; 50(9):2756-2758. PubMed ID: 30401391
[TBL] [Abstract][Full Text] [Related]
27. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
28. Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression.
Saliba F; Fischer L; de Simone P; Bernhardt P; Bader G; Fung J
Ann Transplant; 2018 Oct; 23():751-757. PubMed ID: 30361470
[TBL] [Abstract][Full Text] [Related]
29. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
van Dijk M; van Roon AM; Said MY; Bemelman FJ; Homan van der Heide JJ; de Fijter HW; de Vries APJ; Bakker SJL; Sanders JSF
Transpl Int; 2018 Dec; 31(12):1380-1390. PubMed ID: 30106185
[TBL] [Abstract][Full Text] [Related]
30. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
De Simone P; Saliba F; Dong G; Escrig C; Fischer L
Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
[TBL] [Abstract][Full Text] [Related]
31. The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation.
Deuse T; Bara C; Barten MJ; Hirt SW; Doesch AO; Knosalla C; Grinninger C; Stypmann J; Garbade J; Wimmer P; May C; Porstner M; Schulz U
Contemp Clin Trials; 2015 Nov; 45(Pt B):356-363. PubMed ID: 26363128
[TBL] [Abstract][Full Text] [Related]
32. Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY).
Lee KS; Kim H; Lee SH; Choi DJ; Yoon M; Jeon ES; Choi JO; Kang J; Lee HY; Jung SH; Oh J; Kang SM; Lee SY; Ju MH; Kim JJ; Kim MS; Cho HJ
Transpl Int; 2024; 37():11878. PubMed ID: 38644935
[TBL] [Abstract][Full Text] [Related]
33. Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens.
Bürker BS; Gullestad L; Gude E; Relbo Authen A; Grov I; Hol PK; Andreassen AK; Arora S; Dew MA; Fiane AE; Haraldsen IR; Malt UF; Andersson S
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28185318
[TBL] [Abstract][Full Text] [Related]
34. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).
Manzia TM; Carmellini M; Todeschini P; Secchi A; Sandrini S; Minetti E; Furian L; Spagnoletti G; Pisani F; Piredda GB; Cappelli G; Tisone G
Transplantation; 2020 Feb; 104(2):374-386. PubMed ID: 31335776
[TBL] [Abstract][Full Text] [Related]
35. Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNγ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation.
Iwasaki K; Kitahata N; Miwa Y; Uchida K; Matsuoka Y; Horimi K; Kobayashi T
Ther Drug Monit; 2019 Jun; 41(3):371-375. PubMed ID: 30939587
[TBL] [Abstract][Full Text] [Related]
36. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
37. Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients.
Pacheco LS; Garcia VD; Prá RLD; Cardoso BD; Rodrigues MF; Zanetti HK; Meinerz G; Neumann J; Gnatta D; Keitel E
J Bras Nefrol; 2018; 40(2):143-150. PubMed ID: 29771270
[TBL] [Abstract][Full Text] [Related]
38. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
Carmellini M; Garcia V; Wang Z; Vergara M; Russ G
J Nephrol; 2015 Oct; 28(5):633-9. PubMed ID: 25708913
[TBL] [Abstract][Full Text] [Related]
40. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
